Morgan Stanley Clovis Oncology, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $229,011 - $621,602	-218,106 Reduced 31.08%	483,593 $576,000
Q2 2022 Oct 27, 2022	BUY	$0.63 - $2.96 $45,954 - $215,911	72,943 Added 11.6%	701,699 $1.26 Million
Q2 2022 Aug 15, 2022	BUY	$0.63 - $2.96 $45,954 - $215,911	72,943 Added 11.6%	701,699 $1.26 Million
Q1 2022 Oct 27, 2022	SELL	$1.43 - $3.14 $104,308 - $229,041	-72,943 Reduced 10.4%	628,756 $1.27 Million
Q1 2022 May 13, 2022	BUY	$1.43 - $3.14 $377,824 - $829,628	264,213 Added 72.48%	628,756 $1.27 Million
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $1.81 Million - $3.19 Million	-671,053 Reduced 64.8%	364,543 $988,000
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $4.2 Million - $6.01 Million	1,035,596 New	1,035,596 $4.62 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.